Evotec, Active Biotech in Med-Chem Pact

Evotec AG has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of Active Biotech’s priority biological target involved in immune disorders and cancer. Evotec will now apply its integrated medicinal chemistry platform to optimize initial screening hits with the goal of progressing into a lead optimization program. Financial details were not disclosed.

Dr. Mario Polywka, chief operating officer at Evotec, said, “We are delighted that our screening collaboration with Active Biotech has identified quality hits that we can now progress into a lead identification program. This collaboration is a validation of our hit-finding platform and also the confidence Active Biotech has in Evotec to support the further progress of this project. We look forward to working with the team at Active Biotech in their quest to find novel treatments to address immune disorders and cancer.”